Phase I trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of KOS-1584 administered weekly for 3 weeks every 4 weeks in patients with advanced solid tumors

Trial Profile

Phase I trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of KOS-1584 administered weekly for 3 weeks every 4 weeks in patients with advanced solid tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2007

At a glance

  • Drugs KOS 1584 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Kosan Biosciences; Roche
  • Most Recent Events

    • 28 Feb 2007 Status change from recruiting to in progress.
    • 28 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top